Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06325332 · ClinicalTrials.gov registry record
BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
A clinical trial, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- 49,680
- Enrollment target
NCT06325332 is a clinical trial that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 49,680 participants.
The verdict
NCT06325332 has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- 49,680 participants
- Enrollment target
Study Summary
The primary objectives of the study are: To estimate the effectiveness of nirsevimab against polymerase chain reaction (PCR)-confirmed RSV (1) lower respiratory tract (LRTD) and (2) related medical encounters. the secondary objectives are: 1. To estimate the effectiveness of nirsevimab against medical encounters with a respiratory related diagnosis. 2. To estimate the effectiveness of nirsevimab against medical encounters with an LRTD diagnosis. 3. To estimate the impact of nirsevimab on PCR-confirmed RSV. 4. To estimate the impact of nirsevimab on medical encounters with an otitis media diagnosis. 5. To estimate the impact of nirsevimab on antibiotic prescription.
Interventions
- OTHER Nirsevimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49,680 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06325332
The ClinicalTrials.gov registry entry for NCT06325332 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 49,680 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nirsevimab is the first listed.
NCT06325332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06325332 about?
NCT06325332 is a clinical study titled "BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)". The primary objectives of the study are: To estimate the effectiveness of nirsevimab against polymerase chain reaction (PCR)-confirmed RSV (1) lower respiratory tract (LRTD) and (2) related medical encounters. the secondary objectives are: 1. To estimate the effectiveness of nirsevimab against med...
What is the current status of trial NCT06325332?
This trial is currently completed. The enrollment target is 49,680 participants. The study started on 2024-04-01. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT06325332?
The interventions under investigation include: Nirsevimab (OTHER).
Who is sponsoring clinical trial NCT06325332?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.